Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1509P - Impact of differential diagnosis of cachexia and refractory cachexia and appropriate nutritional support for cachexia on survival in terminal cancer patients

Date

17 Sep 2020

Session

E-Poster Display

Topics

End-of-Life Care

Tumour Site

Presenters

Nobuhisa Nakajima

Citation

Annals of Oncology (2020) 31 (suppl_4): S874-S880. 10.1016/annonc/annonc264

Authors

N. Nakajima

Author affiliations

  • Community-based Medicine And Primary Care, Ryukyu University Hospital, 903-0125 - Okinawa/JP

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1509P

Background

Cachexia appears in many terminal cancer patients and often shifts to refractory cachexia. The purpose of this study was; 1) to identify cachexia patients among the patients judged to have refractory cachexia and 2) to evaluate the impact of appropriate nutritional support for cachexia patients on survival.

Methods

Study subjects were terminal cancer patients who were admitted for terminal care and were judged to have had refractory cachexia in the last 6 years. We retrospectively examined the following Methods: 1) based on prognostic prediction using Palliative Performance Scale (PPS) and Palliative Performance Index (PPI), and biochemical markers (albumin (Alb), transthyretin (TTR), etc.), we distinguished cachexia from refractory cachexia, and 2) we evaluated the change of PPS, PPI, Alb, TTR and survival period of cachexia patients after nutritional support.

Results

Out of 223 patients who were considered to have refractory cachexia on admission, 26 patients improved their general status after palliating symptoms and hydration therapy. We judged them not refractory cachexia but cachexia. We administered nutritional support for these patients and observed significant improvement in several indices (Alb 2.1→3.0, TTR 8.3→21.6, PPS 24→61, p=0.01). When PPS, Alb and TTR were maintained, we judged that nutritional support was effective (Effective group; n=17). When PPS< 50, PPI>6, deterioration of TTR occurred, we judged the transition to refractory cachexia and ceased nutritional support (Non-effective group; n=9). In Effective group, PPS was significantly higher 2 weeks later (P=0.01), and TTR and Alb were significantly higher 3 weeks later (p=0.003, 0.04). Survival period was significantly longer in Effective group (51 vs 23 days, P=0.003).

Conclusions

PPS and TTR were considered to be useful indices for the differential diagnosis of cachexia and refractory cachexia at the terminal stage of cancer, and for the judgement of the indication of nutritional therapy. Change of PPS was the fastest and most useful index for assessing the adequacy of nutritional intervention for cachexia patients. Appropriate nutritional intervention based on these findings may lead to improvements in general condition and prognosis.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.